Become a Readings Member to make your shopping experience even easier. Sign in or sign up for free!

Become a Readings Member. Sign in or sign up for free!

Hello Readings Member! Go to the member centre to view your orders, change your details, or view your lists, or sign out.

Hello Readings Member! Go to the member centre or sign out.

Single Agents in Cancer Chemotherapy
Paperback

Single Agents in Cancer Chemotherapy

$138.99
Sign in or become a Readings Member to add this title to your wishlist.

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

The clinical trials program of anti-tumor drugs was started by the National Cancer Institute in 1955. In the past 15 years, this national network has collected a large body of data on all of the recognized anti-tumor drugs as well as upon new, experimentally promising agents. While the most important of these studies have been published, there has remained a wealth of data not generally available to the scientific community. Drs. Carter and Livingston have not only succeeded in organ~z~ng this large corpus, they have in addition analyzed and interpreted the clinical data in a way that will be highly useful for years to come. From a perusal of this volume it becomes apparent that some drugs are more active against certain tumors than had been realized; that the evidence for the activity of certain drugs against specific tumors is sometimes tenuous; surprisingly, that some highly active agents have never been tried against some of the fairly common tumors. Their monumental work has provided not only access to the hard data, it has also shown the need for research to fill in important gaps in our knowledge. The authors and the IFI/Plenum Press are to be congratulated for this useful and important work. C. Gordon Zubrod, M. D. Scientific Director for Chemotherapy National Cancer Institute National Institutes of Health Bethesda, Maryland v Acknowledgment The authors wish to thank Dr. C. Gordon Zubrod and Dr.

Read More
In Shop
Out of stock
Shipping & Delivery

$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout

MORE INFO
Format
Paperback
Publisher
Springer-Verlag New York Inc.
Country
United States
Date
25 February 2012
Pages
406
ISBN
9781468413809

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

The clinical trials program of anti-tumor drugs was started by the National Cancer Institute in 1955. In the past 15 years, this national network has collected a large body of data on all of the recognized anti-tumor drugs as well as upon new, experimentally promising agents. While the most important of these studies have been published, there has remained a wealth of data not generally available to the scientific community. Drs. Carter and Livingston have not only succeeded in organ~z~ng this large corpus, they have in addition analyzed and interpreted the clinical data in a way that will be highly useful for years to come. From a perusal of this volume it becomes apparent that some drugs are more active against certain tumors than had been realized; that the evidence for the activity of certain drugs against specific tumors is sometimes tenuous; surprisingly, that some highly active agents have never been tried against some of the fairly common tumors. Their monumental work has provided not only access to the hard data, it has also shown the need for research to fill in important gaps in our knowledge. The authors and the IFI/Plenum Press are to be congratulated for this useful and important work. C. Gordon Zubrod, M. D. Scientific Director for Chemotherapy National Cancer Institute National Institutes of Health Bethesda, Maryland v Acknowledgment The authors wish to thank Dr. C. Gordon Zubrod and Dr.

Read More
Format
Paperback
Publisher
Springer-Verlag New York Inc.
Country
United States
Date
25 February 2012
Pages
406
ISBN
9781468413809